Cabaletta Bio engineers a patient's own immune cells to hunt down and destroy the specific B cells causing autoimmune diseases like pemphigus vulgaris. Think of it as a precision strike against the body's own faulty antibody factories.
Cabaletta is a clinical-stage biotech with no approved products, so it generates no revenue. The company is burning through cash to fund research, with a net loss of USD 0.17B in 2025.
Cabaletta's CAAR platform is highly specialized, but the company is years away from a marketable product and faces intense competition from larger, better-funded players like Novartis and Bristol Myers Squibb. Its moat is weak because it has no proprietary dat
Key events, in time order
None yet
None yet
The post is a link to an article about Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune diseases.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
